{"doc_id": "33707061", "type of study": "Therapy", "title": "", "abstract": "A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.\nVaccines are urgently needed to prevent the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).\nWe assessed the safety and immunogenicity of vaccine candidate mRNA-1273, encoding the prefusion-stabilized spike protein of SARS-CoV-2.\nThis phase 2, randomized, observer-blind, placebo-controlled trial was conducted at 8 sites in the USA, in healthy adults aged\u00a0\u226518\u00a0years with no known history or risk of SARS-CoV-2 infection, and had not previously received an investigational CoV vaccine or treatment.\nParticipants were stratified into two age cohorts (\u226518-<55 and\u00a0\u226555) and were randomly assigned (1:1:1) to either 50 or 100\u00a0\u00b5g of mRNA-1273, or placebo administered as two intramuscular injections 28\u00a0days apart.\nThe primary outcomes were safety, reactogenicity, and immunogenicity assessed by anti-SARS-CoV-2-spike binding antibody level (bAb).\nSecondary outcome was immunogenicity assessed by SARS-CoV-2 neutralizing antibody (nAb) response.\nBetween 29 May and 8 July 2020, 600 participants were randomized, 300 per age cohort.\nThe most common solicited adverse reactions were pain at injection site, headache, and fatigue following each vaccination in both age cohorts.\nOne serious adverse event deemed unrelated by the site investigator occurred 33\u00a0days post-vaccination one.\nmRNA-1273 induced bAb and nAb by 28\u00a0days post-vaccination one that were higher at the 100\u00a0\u00b5g dose relative to the 50\u00a0\u00b5g dose; this difference was less apparent post-vaccination two.\nBinding antibodies and nAb increased substantially by 14\u00a0days following the second vaccination (day 43) to levels exceeding those of convalescent sera and remained elevated through day 57.\nVaccination with mRNA-1273 resulted in significant immune responses to SARS-CoV-2 in participants 18\u00a0years and older, with an acceptable safety profile, confirming the safety and immunogenicity of 50 and 100 \u00b5g mRNA-1273 given as a 2 dose-regimen.\nClinicalTrials.gov; NCT04405076.\nCopyright \u00a9 2021 Moderna Therapeutics. Published by Elsevier Ltd.. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "healthy", "negation": "affirmed", "UMLS": {}, "start": 111, "end": 118}, {"term": "risk of SARS-CoV-2 infection", "negation": "negated", "UMLS": {}, "start": 166, "end": 194}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "mRNA-1273 SARS-CoV-2 vaccine", "negation": "affirmed", "UMLS": {}, "start": 98, "end": 126}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 69, "end": 75}, {"term": "immunogenicity", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 94}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Vaccines are urgently needed to prevent the global spread of severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "We assessed the safety and immunogenicity of vaccine candidate mRNA-1273 , encoding the prefusion-stabilized spike protein of SARS-CoV-2 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "vaccine candidate mRNA-1273", "negation": "affirmed", "UMLS": {}, "start": 45, "end": 72}], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 22}, {"term": "immunogenicity", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 41}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This phase 2 , randomized , observer-blind , placebo-controlled trial was conducted at 8 sites in the USA , in healthy adults aged \u226518 years with no known history or risk of SARS-CoV-2 infection , and had not previously received an investigational CoV vaccine or treatment .", "Evidence Elements": {"Participant": [{"term": "healthy", "negation": "affirmed", "UMLS": {}, "start": 111, "end": 118}, {"term": "risk of SARS-CoV-2 infection", "negation": "negated", "UMLS": {}, "start": 166, "end": 194}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Participants were stratified into two age cohorts ( \u226518- < 55 and \u226555 ) and were randomly assigned ( 1:1:1 ) to either 50 or 100 \u00b5g of mRNA-1273 , or placebo administered as two intramuscular injections 28 days apart .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "50 or 100 \u00b5g of mRNA-1273", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 144}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 150, "end": 157}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcomes were safety , reactogenicity , and immunogenicity assessed by anti-SARS-CoV-2-spike binding antibody level ( bAb ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 32}, {"term": "reactogenicity", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 49}, {"term": "immunogenicity", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 70}, {"term": "anti-SARS-CoV-2-spike binding antibody", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 121}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Secondary outcome was immunogenicity assessed by SARS-CoV-2 neutralizing antibody ( nAb ) response .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "immunogenicity", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 36}, {"term": "SARS-CoV-2 neutralizing antibody ( nAb", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 87}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Between 29 May and 8 July 2020 , 600 participants were randomized , 300 per age cohort .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The most common solicited adverse reactions were pain at injection site , headache , and fatigue following each vaccination in both age cohorts .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "both", "negation": "affirmed", "UMLS": {}, "start": 127, "end": 131}], "Outcome": [{"term": "pain at injection site", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 71}, {"term": "headache", "negation": "affirmed", "UMLS": {}, "start": 74, "end": 82}, {"term": "fatigue", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 96}], "Observation": [{"term": "most common", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 15}], "Count": []}, "Evidence Propositions": [{"Intervention": ["both"], "Observation": "most common", "Outcome": "pain at injection site", "Count": ""}, {"Intervention": ["both"], "Observation": "most common", "Outcome": "headache", "Count": ""}, {"Intervention": ["both"], "Observation": "most common", "Outcome": "fatigue", "Count": ""}]}, {"Section": "RESULTS", "Text": "One serious adverse event deemed unrelated by the site investigator occurred 33 days post-vaccination one .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "serious adverse event", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 25}], "Observation": [], "Count": [{"term": "One", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 3}, {"term": "one", "negation": "affirmed", "UMLS": {}, "start": 102, "end": 105}]}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "mRNA-1273 induced bAb and nAb by 28 days post-vaccination one that were higher at the 100 \u00b5g dose relative to the 50 \u00b5g dose ; this difference was less apparent post-vaccination two .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "mRNA-1273", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 9}, {"term": "100 \u00b5g dose", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 97}, {"term": "50 \u00b5g dose", "negation": "affirmed", "UMLS": {}, "start": 114, "end": 124}], "Outcome": [{"term": "bAb", "negation": "affirmed", "UMLS": {}, "start": 18, "end": 21}, {"term": "nAb", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 29}], "Observation": [{"term": "higher", "negation": "affirmed", "UMLS": {}, "start": 72, "end": 78}, {"term": "difference", "negation": "affirmed", "UMLS": {}, "start": 132, "end": 142}, {"term": "less apparent", "negation": "affirmed", "UMLS": {}, "start": 147, "end": 160}], "Count": []}, "Evidence Propositions": [{"Intervention": ["mRNA-1273", "100 \u00b5g dose", "50 \u00b5g dose"], "Observation": "higher", "Outcome": "nAb", "Count": ""}, {"Intervention": [], "Observation": "difference", "Outcome": "", "Count": ""}, {"Intervention": [], "Observation": "less apparent", "Outcome": "", "Count": ""}]}, {"Section": "RESULTS", "Text": "Binding antibodies and nAb increased substantially by 14 days following the second vaccination ( day 43 ) to levels exceeding those of convalescent sera and remained elevated through day 57 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Binding antibodies", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 18}, {"term": "nAb", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 26}], "Observation": [{"term": "increased substantially", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 50}, {"term": "remained elevated", "negation": "affirmed", "UMLS": {}, "start": 157, "end": 174}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "Vaccination with mRNA-1273 resulted in significant immune responses to SARS-CoV-2 in participants 18 years and older , with an acceptable safety profile , confirming the safety and immunogenicity of 50 and 100 \u00b5g mRNA-1273 given as a 2 dose-regimen .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "mRNA-1273", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 26}, {"term": "50 and 100 \u00b5g", "negation": "affirmed", "UMLS": {}, "start": 199, "end": 212}, {"term": "mRNA-1273", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 26}], "Outcome": [{"term": "immune responses to SARS-CoV-2", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 81}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 138, "end": 144}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 138, "end": 144}, {"term": "immunogenicity", "negation": "affirmed", "UMLS": {}, "start": 181, "end": 195}], "Observation": [{"term": "significant", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 50}, {"term": "acceptable", "negation": "affirmed", "UMLS": {}, "start": 127, "end": 137}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "ClinicalTrials.gov ; NCT04405076 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2021 Moderna Therapeutics . Published by Elsevier Ltd . . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}